PPARG and breast carcinoma: Western blot analysis shows that treatment with subeffective doses of γ-tocotrienol (2 μM), rosiglitazone (3.2 μM), or GW9662 (3.2 μM) alone or in combination had no significant effect on PPARγ levels in vehicle-treated or scrambled RNA transfected MCF-7 (Figure 8(a)) and MDA-MB-231 (Figure 8(b)) breast cancer cells.